Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silke Lassmann

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Frontiers in Oncology|December 15, 2025
Comprehensive molecular profiling of urologic tumors presented in a molecular tumor board: insights from a real-world precision oncology cohortMaximilian Glienke, Ruth Himmelsbach, Max Zirngibl, et al.
Pediatric Blood & Cancer|June 10, 2017
Epithelioid hemangioendotheliomas of the liver and lung in children and adolescentsSimone Hettmer, Geoffroy Andrieux, Jochen Hochrein, et al.
International Journal of Colorectal Disease|August 16, 2008
Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapyBjörn L D M Brücher, Gisela Keller, Martin Werner, et al.
Cancer Research|November 9, 2014
B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cellsRicarda Herr, Martin Köhler, Hana Andrlová, et al.
The Journal of Experimental Medicine|January 22, 2004
The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitisNaoto Kawakami, Silke Lassmann, Zhaoxia Li, et al.
Ebiomedicine|May 14, 2017
The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive BehaviorFlorian Weinberg, Nadine Reischmann, Lisa Fauth, et al.
Nature Immunology|November 6, 2023
Harnessing CD3 diversity to optimize CAR T cellsRubí M-H Velasco Cárdenas, Simon M Brandl, Ana Valeria Meléndez, et al.
Molecular Oncology|October 15, 2021
Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancerSilvia Waldeck, Jan Mitschke, Sebastian Wiesemann, et al.
ACS Chemical Biology|July 10, 2019
The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone DemethylasesMartin Roatsch, Inga Hoffmann, Martine I Abboud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerPhilip Bischoff, Martin Reck, Tobias Overbeck, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Frontiers in Oncology|December 15, 2025
Comprehensive molecular profiling of urologic tumors presented in a molecular tumor board: insights from a real-world precision oncology cohortMaximilian Glienke, Ruth Himmelsbach, Max Zirngibl, et al.
Pediatric Blood & Cancer|June 10, 2017
Epithelioid hemangioendotheliomas of the liver and lung in children and adolescentsSimone Hettmer, Geoffroy Andrieux, Jochen Hochrein, et al.
International Journal of Colorectal Disease|August 16, 2008
Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapyBjörn L D M Brücher, Gisela Keller, Martin Werner, et al.
Cancer Research|November 9, 2014
B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cellsRicarda Herr, Martin Köhler, Hana Andrlová, et al.
The Journal of Experimental Medicine|January 22, 2004
The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitisNaoto Kawakami, Silke Lassmann, Zhaoxia Li, et al.
Ebiomedicine|May 14, 2017
The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive BehaviorFlorian Weinberg, Nadine Reischmann, Lisa Fauth, et al.
Nature Immunology|November 6, 2023
Harnessing CD3 diversity to optimize CAR T cellsRubí M-H Velasco Cárdenas, Simon M Brandl, Ana Valeria Meléndez, et al.
Molecular Oncology|October 15, 2021
Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancerSilvia Waldeck, Jan Mitschke, Sebastian Wiesemann, et al.
ACS Chemical Biology|July 10, 2019
The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone DemethylasesMartin Roatsch, Inga Hoffmann, Martine I Abboud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerPhilip Bischoff, Martin Reck, Tobias Overbeck, et al.
Pageof 8